JP2020537649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537649A5 JP2020537649A5 JP2020520804A JP2020520804A JP2020537649A5 JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- heavy chain
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183034A JP2024012366A (ja) | 2017-10-14 | 2023-10-25 | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572467P | 2017-10-14 | 2017-10-14 | |
| US62/572,467 | 2017-10-14 | ||
| PCT/US2018/055733 WO2019075417A1 (en) | 2017-10-14 | 2018-10-12 | CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183034A Division JP2024012366A (ja) | 2017-10-14 | 2023-10-25 | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537649A JP2020537649A (ja) | 2020-12-24 |
| JP2020537649A5 true JP2020537649A5 (enExample) | 2021-07-26 |
| JP7374891B2 JP7374891B2 (ja) | 2023-11-07 |
Family
ID=64110112
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520804A Active JP7374891B2 (ja) | 2017-10-14 | 2018-10-12 | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 |
| JP2023183034A Pending JP2024012366A (ja) | 2017-10-14 | 2023-10-25 | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183034A Pending JP2024012366A (ja) | 2017-10-14 | 2023-10-25 | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 |
Country Status (36)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| TWI726879B (zh) * | 2015-05-04 | 2021-05-11 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| EP3635009B1 (en) | 2017-06-07 | 2026-02-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| HUE054037T2 (hu) * | 2017-10-14 | 2021-08-30 | Abbvie Inc | CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra |
| IL276464B2 (en) | 2018-02-07 | 2026-01-01 | Regeneron Pharma | Methods and compositions for administering therapeutic protein |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| MA52626A (fr) | 2018-05-17 | 2021-03-24 | Regeneron Pharma | Anticorps anti-cd63, conjugués et leurs utilisations |
| WO2021205358A1 (en) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Compositions and methods for blood-brain barrier delivery |
| MX2022011780A (es) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics Inc | Composiciones que contienen anticuerpos activables. |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| AU2022388735A1 (en) | 2021-11-09 | 2024-05-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| AU2023314808A1 (en) * | 2022-07-29 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025133132A1 (en) * | 2023-12-20 | 2025-06-26 | Institut National De La Sante Et De La Recherche Medicale | Novel anti-tfr1 (cd71) antibodies for cancer treatment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US7666817B2 (en) | 2005-08-31 | 2010-02-23 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2224954B1 (en) * | 2007-11-07 | 2014-01-08 | Celldex Therapeutics, Inc. | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| AU2010241706B2 (en) * | 2009-04-29 | 2015-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| ES2700514T3 (es) * | 2011-02-01 | 2019-02-18 | Genmab As | Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74 |
| KR102098413B1 (ko) * | 2012-01-31 | 2020-04-07 | 에스비아이 바이오테크 가부시키가이샤 | 항-포스포리파아제 ｄ4 항체 |
| WO2014026136A2 (en) | 2012-08-10 | 2014-02-13 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| CN103145847B (zh) * | 2013-02-05 | 2014-05-21 | 浙江大学 | 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用 |
| TWI726879B (zh) | 2015-05-04 | 2021-05-11 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| CN106237341B (zh) * | 2016-07-12 | 2019-07-30 | 浙江大学 | 一种抗体偶联药物及其制备方法和应用 |
| HUE054037T2 (hu) * | 2017-10-14 | 2021-08-30 | Abbvie Inc | CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra |
-
2018
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en not_active Abandoned
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active Active
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en not_active Ceased
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko not_active Expired - Fee Related
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en not_active Withdrawn
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko not_active Withdrawn
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh not_active IP Right Cessation
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Ceased
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
-
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
-
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537649A5 (enExample) | ||
| HRP20210436T1 (hr) | Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe | |
| JP2022064924A5 (enExample) | ||
| JP2020500016A5 (enExample) | ||
| JP2020506900A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| HRP20241563T1 (hr) | Postupak liječenja ili ublažavanja metaboličkih poremećaja primjenom agonista glp-1 receptora konjugiranih na antagoniste želučanog inhibitornog peptidnog receptora (gipr) | |
| JP2024016177A5 (enExample) | ||
| EP4588940A3 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JP2020500538A5 (enExample) | ||
| JP2020519643A5 (enExample) | ||
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| JP2015120706A5 (enExample) | ||
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| RU2010116152A (ru) | Антитело против рецептора il-6 | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr |